NBY.Novabay Pharmaceuticals, INC

S-1/A: NovaBay Pharmaceuticals Eyes $3.16 Million Boost Through Stock and Warrant Offering

Sentiment:

S-1/A Filing

📋All filings for Novabay Pharmaceuticals, INC
🔒Login to Follow

NovaBay Pharmaceuticals aims to raise approximately $3.16 million through a public offering of common stock and warrants to fund working capital and general corporate purposes.

Capital raiseNovaBay is offering up to 1,643,192 shares of common stock and accompanying warrants, or pre-funded warrants in lieu of common stock.The assumed combined public offering price is $2.13 per share and accompanying warrants.The company estimates net proceeds of approximately $3.16 million, or $3.68 million if the underwriter's option is fully exercised.
Worse than expectedThe company has a history of operating losses and expects expenses to exceed revenues in 2024.There is substantial doubt about the company's ability to continue as a going concern.The company is not in compliance with NYSE American continued listing requirements.

Summary

  • NovaBay Pharmaceuticals is undertaking a public offering to sell up to 1,643,192 shares of common stock along with Series F-1, F-2, and F-3 warrants, or pre-funded warrants in lieu of common stock.
  • The assumed combined public offering price is $2.13 per share and accompanying warrants.
  • The company estimates net proceeds of approximately $3.16 million, or $3.68 million if the underwriter's option is fully exercised.
  • A portion of the proceeds, estimated at $561,700, will be used to redeem outstanding Secured Convertible Notes.
  • The remaining funds will be allocated for working capital and general corporate purposes.
  • Preliminary second quarter results project net revenue of approximately $2.4 million for the three months ended June 30, 2024, and $5.0 million for the six months ended June 30, 2024.
  • Cash and cash equivalents as of June 30, 2024, are estimated at $0.8 million, with net cash used in continuing operations in the second quarter of 2024 at $1.1 million.
  • The company has granted the underwriter an option to purchase up to 246,479 additional shares and/or warrants to cover over-allotments.
  • The offering includes a one-time reset of the exercise price for the warrants 60 days after issuance, based on 90% of the five-day volume weighted average price.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the capital raise is a positive step, the company's financial struggles and going concern doubts weigh heavily, resulting in a neutral to slightly negative outlook.

Positives

  • The offering will provide additional capital to fund operations and commercialization efforts.
  • The redemption of Secured Convertible Notes will reduce the company's debt.
  • The warrants may incentivize investors with the potential for future gains.
  • The company has a plan to regain compliance with NYSE American listing standards by October 18, 2025.

Negatives

  • The company has a history of operating losses and expects expenses to exceed revenues in 2024.
  • There is substantial doubt about the company's ability to continue as a going concern.
  • Existing stockholders will experience dilution as a result of the offering.
  • The company is not in compliance with NYSE American continued listing requirements.
  • The company had net cash used in continuing operations in the second quarter of 2024 at $1.1 million.

Risks

  • The company's future success depends on the successful commercialization of its products, particularly Avenova Spray.
  • The company faces substantial competition in the eyecare market.
  • The company is dependent on third parties to manufacture, supply, and distribute its products.
  • The company's ability to use net operating loss carryforwards may be limited.
  • The price of the company's common stock may fluctuate substantially.
  • The company may be subject to product liability claims.
  • The company may be unable to protect its intellectual property.
  • The company may face enforcement action from the FDA.
  • The company may be delisted from the NYSE American.

Future Outlook

The company believes that the net proceeds from this offering, together with existing cash and cash equivalents, will meet capital needs through the fourth quarter of 2024 and support continued commercialization efforts and be used for working capital and general corporate purposes.

Industry Context

NovaBay operates in the competitive eyecare and wound care markets, facing established players and generic alternatives. The company differentiates itself through its proprietary hypochlorous acid formulations and doctor-recommended brand image.

Comparison to Industry Standards

  • The document mentions competitors such as Allergan plc and Shire plc in the eyecare market.
  • It also notes competition from products like Restasis, Xiidra, eye wipes, baby shampoo, and soap.
  • In the wound care market, NeutroPhase and PhaseOne compete with products like Vashe and Betadine Surgical Scrub.
  • The document does not provide specific comparisons of NovaBay's financial performance or market share to these competitors.

Stakeholder Impact

  • Shareholders will experience dilution as a result of the offering.
  • The offering aims to provide financial stability to the company, potentially benefiting employees and other stakeholders.
  • Customers may see continued availability of NovaBay's products.
  • Creditors will see a portion of the company's debt redeemed.

Next Steps

  • The company will proceed with the public offering of common stock and warrants.
  • The company will use a portion of the proceeds to redeem outstanding Secured Convertible Notes.
  • The company will allocate the remaining funds for working capital and general corporate purposes.
  • The company will continue to execute its plan to regain compliance with NYSE American listing standards.
  • The company will be subject to quarterly monitoring for compliance with the plan.

Key Dates

DateDescription
January 19, 2000NovaBay was incorporated in California as NovaCal Pharmaceuticals, Inc.
July 1, 2002NovaCal Pharmaceuticals, Inc. acquired all operating assets of NovaCal Pharmaceuticals, LLC.
February 2007NovaCal Pharmaceuticals, Inc. changed its name to NovaBay Pharmaceuticals, Inc.
June 2010The Company changed the state in which it was incorporated and is now incorporated under the laws of the State of Delaware.
November 2, 2021NovaBay issued and sold 15,000 shares of Series B Preferred Stock.
January 29, 2024The anti-dilution protection for the Series B Preferred Stock expired.
March 12, 2024NovaBay entered into a Membership Unit Purchase Agreement to sell 100% of the membership units of DERMAdoctor to New Age Investments, LLC.
March 25, 2024The DERMAdoctor Divestiture closed, with NovaBay selling the DERMAdoctor membership units to New Age Investments, LLC for $1.1 million.
March 24, 2024The Company and the secured parties entered into a First Amendment to the Security Agreement to effect the Security Agreement Amendment, or the First Amendment, and a Consent and Release to effect the Subsidiary Guarantee Termination, or the Subsidiary Guarantee Consent.
April 18, 2024NovaBay received a notification from the NYSE American stating that the Company is not in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.
May 28, 2024NovaBay received a further notification from the NYSE American, stating that the Company is not in compliance with Section 1003(a)(i) of the NYSE American Company Guide.
May 28, 2024At the 2024 Annual Meeting of Stockholders, stockholders approved a Certificate of Amendment to effect a reverse stock split.
May 29, 2024NovaBay announced that its Board of Directors established the reverse stock split ratio of 1-for-35.
May 30, 2024The reverse stock split became effective.
May 31, 2024The common stock began trading on a split-adjusted basis.
June 4, 2024The Company received notice from the NYSE American that it had accepted the Companys plan of compliance and granted a plan period through October 18, 2025.
June 14, 2024NovaBay entered into letter agreements with existing warrant holders to exercise a portion of their warrants at a reduced price.
December 17, 2024Series E warrants issued in the warrant reprice transaction will be exercisable beginning on this date.
October 18, 2025The deadline for NovaBay to regain compliance with NYSE American listing standards.
July 23, 2024The last reported sale price of NovaBay's common stock on the NYSE American was $2.13 per share.

Keywords

common stock, warrants, offering, NovaBay, pharmaceuticals, Avenova, Securities, capital, funding, dilution

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.